These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29374532)

  • 21. Inhibition of protein misfolding and aggregation by natural phenolic compounds.
    Dhouafli Z; Cuanalo-Contreras K; Hayouni EA; Mays CE; Soto C; Moreno-Gonzalez I
    Cell Mol Life Sci; 2018 Oct; 75(19):3521-3538. PubMed ID: 30030591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why are Functional Amyloids Non-Toxic in Humans?
    Jackson MP; Hewitt EW
    Biomolecules; 2017 Sep; 7(4):. PubMed ID: 28937655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting protein aggregation with nanomaterials: The underlying mechanisms and impact factors.
    Wang S; Zheng J; Ma L; Petersen RB; Xu L; Huang K
    Biochim Biophys Acta Gen Subj; 2022 Feb; 1866(2):130061. PubMed ID: 34822925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune Responses to Soluble Aggregates of Amyloidogenic Proteins Involved in Neurodegenerative Diseases: Overlapping Aggregation Prone and Autoimmunogenic regions.
    Kumar S; Thangakani AM; Nagarajan R; Singh SK; Velmurugan D; Gromiha MM
    Sci Rep; 2016 Feb; 6():22258. PubMed ID: 26924748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.
    Stefani M; Dobson CM
    J Mol Med (Berl); 2003 Nov; 81(11):678-99. PubMed ID: 12942175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloids and Amyloid-like Protein Aggregates in Foods: Challenges and New Perspectives.
    Malik S; Yadav JK
    Curr Protein Pept Sci; 2023; 24(5):393-403. PubMed ID: 36600621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of amyloid disaggregation.
    Low KJY; Venkatraman A; Mehta JS; Pervushin K
    J Adv Res; 2022 Feb; 36():113-132. PubMed ID: 35127169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Process, Outcomes and Possible Elimination of Aggregation with Special Reference to Heme Proteins; Likely Remediations of Proteinopathies.
    Furkan M; Khan RH
    Curr Protein Pept Sci; 2020; 21(6):573-583. PubMed ID: 32013844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloidogenicity at a Distance: How Distal Protein Regions Modulate Aggregation in Disease.
    Lucato CM; Lupton CJ; Halls ML; Ellisdon AM
    J Mol Biol; 2017 May; 429(9):1289-1304. PubMed ID: 28342736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Misfolding of amyloidogenic proteins and their interactions with membranes.
    Relini A; Marano N; Gliozzi A
    Biomolecules; 2013 Dec; 4(1):20-55. PubMed ID: 24970204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Gelsolin Pathogenic D187N Mutant Exhibits Altered Conformational Stability and Forms Amyloidogenic Oligomers.
    Srivastava A; Singh J; Singh Yadav SP; Arya P; Kalim F; Rose P; Ashish ; Kundu B
    Biochemistry; 2018 Apr; 57(16):2359-2372. PubMed ID: 29637772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro.
    Ozawa D; Nomura R; Mangione PP; Hasegawa K; Okoshi T; Porcari R; Bellotti V; Naiki H
    Sci Rep; 2016 Jul; 6():29077. PubMed ID: 27380955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid-Forming Segment Induces Aggregation of FUS-LC Domain from Phase Separation Modulated by Site-Specific Phosphorylation.
    Ding X; Sun F; Chen J; Chen L; Tobin-Miyaji Y; Xue S; Qiang W; Luo SZ
    J Mol Biol; 2020 Jan; 432(2):467-483. PubMed ID: 31805282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
    Horvath I; Wittung-Stafshede P
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12473-12477. PubMed ID: 27791129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of protein structure instability: from physiological to pathological secondary structure.
    Sukhanova A; Poly S; Shemetov A; Bronstein I; Nabiev I
    Biopolymers; 2012 Aug; 97(8):577-88. PubMed ID: 22605549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-polyphenolic natural inhibitors of amyloid aggregation.
    Ma L; Yang C; Zheng J; Chen Y; Xiao Y; Huang K
    Eur J Med Chem; 2020 Apr; 192():112197. PubMed ID: 32172082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational diseases: looking into the eyes.
    Surguchev A; Surguchov A
    Brain Res Bull; 2010 Jan; 81(1):12-24. PubMed ID: 19808079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
    Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
    Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.